Spectranetics to Attend Upcoming Investor Conferences

COLORADO SPRINGS, Colo., Nov. 07, 2016 (GLOBE NEWSWIRE) -- The Spectranetics Corporation (NASDAQ: SPNC), (“the Company”) today announced that company management will be attending three upcoming investor conferences.

On November 16th, 2016, the Company will attend the Stifel Healthcare Conference at the Lotte New York Palace Hotel. The fireside chat will begin at 8:45 am Eastern Standard Time and can be accessed via the live webcast at http://wsw.com/webcast/stifel5/spnc.

On November 17th, 2016, the Company will attend the Canaccord Genuity Medical Technologies & Diagnostics Forum. The fireside chat will begin at 10 am Eastern Standard Time and can be accessed via the live webcast at http://wsw.com/webcast/canaccord24/spnc.

Additionally, on November 30th, 2016, the Company will attend the 28th Annual Piper Jaffray Healthcare Conference. Webcasting details will be available two weeks prior to the event.

Access to each of the three webcasts will also be available in the Events section of the Investor Relations website at http://www.spectranetics.com/investor-relations/investor-events. 

About Spectranetics

The Spectranetics Corporation develops, manufactures, markets and distributes medical devices used in minimally invasive procedures within the cardiovascular system. The Company's products are available in over 65 countries and are used to treat arterial blockages in the heart and legs and in the removal of pacemaker and defibrillator leads.

The Company's Vascular Intervention (VI) products include a range of laser catheters for ablation of blockages in arteries above and below the knee, the AngioSculpt scoring balloon used in both peripheral and coronary procedures, and the Stellarex drug-coated balloon peripheral angioplasty platform, which received European CE mark approval in December 2014. The Company also markets support catheters to facilitate crossing of peripheral and coronary arterial blockages, and retrograde access and guidewire retrieval devices used in the treatment of peripheral arterial blockages, including chronic total occlusions. The Company markets aspiration and cardiac laser catheters to treat blockages in the heart.

The Lead Management (LM) product line includes excimer laser sheaths, dilator sheaths, mechanical sheaths and accessories for the removal of pacemaker and defibrillator cardiac leads.

For more information, visit www.spectranetics.com.

Investor Relations Contacts
Zach Stassen   
Sr. Director of Finance 
[email protected] 
(719) 447-2292  

Michaella Gallina
Director of Investor Relations
[email protected]
(719) 447-2417

Source: The Spectranetics Corporation

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• FuelCell Energy signs deal with Fit Energy for up to 380 MW of power
• Lead Real Estate Expands Luxury Residential and Extended-Stay Hospitality Footprint in Central Tokyo
• Zodiac Gold closes C$5.6M private placement for Todi drill program